Today The Partnership for Safe Medicines filed comments with Health and Human Services about the dangers posed by its draft regulations for state-based Canadian drug importation programs. PSM cited historic problems with and patient harm from Canadian vendors selling counterfeit medications to U.S. patients and medical practices; showed broad opposition to the plan by Canadian stakeholders; and provides alternatives that don’t impact patient safety.